Analysis of the Association between the Tgfb1 Gene Haplotype and Liver Diseases in Children.

Transforming growth factor-β1 (TGF-β1), a cytokine with immunosuppressive and pro-fibrogenic activity, is a potential marker of infection, liver transplant rejection, and fibrosis. Its levels in the blood and tissues depend on many factors; however, the role of gene polymorphism is still unclear. In this work, the distribution frequency of three single nucleotide polymorphism (SNP) variants of the gene, namely rs1800469, rs1800470, and rs1800471, was studied in children with end-stage liver disease (ESLD).

Time is of the essence: A single-center experience of hepatic arterial supply impairment management in pediatric liver transplant recipients.

Background: Impairment of hepatic arterial flow including hepatic arterial thrombosis (HAT), hepatic arterial stenosis (HAS), and splenic artery steal syndrome (SASS) is potentially life-threatening complications. The proposed early diagnosis and urgent treatment strategy of graft arterial flow reduction aim to decrease morbidity and mortality.

Methods: Pediatric patients with known hepatic arterial flow impairment were retrospectively reviewed.

Transforming growth factor beta 1 levels in the blood of pediatric liver recipients: Clinical and biochemical correlations.

TGF-β1 is a cytokine with profibrogenic and immunosuppressive activities, which suggest the clinical significance of TGF-β1 for the assessment of graft function after LT. We analyzed the dynamics of TGF-β1 levels in the blood after LDLT in 135 pediatric liver recipients and examined the relationship between the cytokine levels and the laboratory and clinical variables. We found that TGF-β1 levels in the blood of patients with ESLD were lower than that in healthy children of the same age, P = .

Deceased vs living donor grafts for pediatric simultaneous liver-kidney transplantation: A single-center experience.

Introduction: In conditions of limited experience of pediatric simultaneous liver-kidney transplantation (SLKT) using grafts from living and deceased donors, there is a certain need to validate the approach.

Patients: The retrospective study of 18 pediatric patients who received SLKT between 2008 and 2019.

Results: Grafts were obtained from both living and deceased donors.

Effects of Growth Factors on Mobilization of Mesenchymal Stem Cells.

We studied mobilization of bone marrow stem cells the under conditions of boost-therapy with granulocytic CSF and erythropoietin. Immunophenotyping of the peripheral blood was carried out in patients after transplantation of tissue-engineered trachea during the perioperative period. We observed an increase in hemopoietic stem cell pool and appearance of multipotent mesenchymal stromal cells in systemic circulation, their maximum concentration being recorded on days 10-14 after surgery.